Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
By: Bondok, Rania M., Barakat, Lamiaa A., Elsergany, Alyaa R., Mahsoub, Nancy, Ghattas, Maivel H.

BioMed Central
2023-06-23; doi: 10.1186/s12885-023-11071-2

Abstract

Objective

The study aimed to investigate the over expression of IFITM3 in hepatocellular carcinoma Egyptian patients.

Background

Hepatocellular carcinoma (HCC) continues to be a serious disease burden. Interferon Induced Transmembrane protein 3 (IFITM3) is a protein that encoded in humans by the IFITM3 gene. It plays a critical role in the immune system’s defense, responsible for a large portion of the antiviral activity. In this study, we showed that IFITM3 rs 12252-CC was over expressed in HCC patients compared to control group with HCV infection.

Method

DNA sequencing was applied for detection of IFITM3 rs 12252-CC and IFITM3 protein level was measured by ELISA to 50 patients with HCC with cirrhosis and 50 with Hepatitis C virus infection.

Results

The obtained results of this study indicated that IFITM3 rs 12252-CC was significantly elevated in HCC group, the codominant model of CC genotype of IFITM3 gene had high association with risk of hepatocellular carcinoma with odd ratio (OR) = 2.70, p = 0.041.

Conclusion

IFITM3 play an important role in progression of hepatocellular carcinoma. Results revealed that IFITM3 rs 12252-CC among Hepatocellular carcinoma patients would allow diagnosis and starting intervention.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements